Early Phase 1 Refractory Clinical Trials
31 recruitingEarly Phase 1
What is a Early Phase 1 trial?
Early Phase 1 trials are the earliest stage of testing in humans. These small studies focus on how a drug is processed in the body and how it affects the body, often enrolling just a handful of participants to establish initial safety data.
Showing 1–20 of 31 trials
Recruiting
Early Phase 1
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Suzhou Immunofoco Biotechnology Co., Ltd30 enrolled4 locationsNCT07493135
Recruiting
Early Phase 1
A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases
Relapsed/Refractory Autoimmune Diseases
Beijing Boren Hospital18 enrolled1 locationNCT07448298
Recruiting
Early Phase 1
An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease
Relapsed/Refractory Immune NephropathyRelapsed/Refractory Immune-mediated Kidney Disease
Changhai Hospital36 enrolled1 locationNCT07241468
Recruiting
Early Phase 1
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center9 enrolled1 locationNCT05800405
Recruiting
Early Phase 1
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
IgA Nephropathy (IgAN)Membranous NephropathyANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN)+2 more
Grit Biotechnology30 enrolled1 locationNCT07389499
Recruiting
Early Phase 1
Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases
Relapsed/Refractory B Cell-Mediated Autoimmune Diseases
Ruijin Hospital27 enrolled1 locationNCT07322718
Recruiting
Early Phase 1
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Relapsing or Refractory Multiple Sclerosis (MS)Myasthenia Gravis (MG)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)+1 more
Daishi Tian36 enrolled1 locationNCT07337785
Recruiting
Early Phase 1
Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma
Multiple MyleomaRefractory and Relapsed Multiple Myeloma
Wondercel Biotech (ShenZhen)30 enrolled1 locationNCT06663046
Recruiting
Early Phase 1
the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
Recurrent or Refractory Systemic Lupus ErythematosusRecurrent or Refractory IgG4 Related DiseasesRecurrent or Refractory Systemic Sclerosis+2 more
Tongji Hospital45 enrolled1 locationNCT07339540
Recruiting
Early Phase 1
A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases
Moderate to Severe Refractory Autoimmune Disease
Grit Biotechnology22 enrolled1 locationNCT07333118
Recruiting
Early Phase 1
A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
Relapsed/Refractory Autoimmune Diseases
Nanjing Legend Biotech Co.36 enrolled5 locationsNCT07095075
Recruiting
Early Phase 1
Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies
Relapsed/Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology6 enrolled1 locationNCT07240974
Recruiting
Early Phase 1
Optimization of Deep Brain Stimulation Parameters in Patients With Medically Refractory Epilepsy
Refractory EpilepsyDeep Brain Stimulation
University of Minnesota20 enrolled1 locationNCT05493722
Recruiting
Early Phase 1
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Plasma Cell Leukemia
The First Affiliated Hospital of Soochow University24 enrolled1 locationNCT06730256
Recruiting
Early Phase 1
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory
Beijing GoBroad Hospital48 enrolled3 locationsNCT07093411
Recruiting
Early Phase 1
Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma
RefractoryRetinoblastoma
Eye & ENT Hospital of Fudan University2 enrolled1 locationNCT06424301
Recruiting
Early Phase 1
A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
Multiple MyelomaRelapsed/Refractory
The First Affiliated Hospital of Nanchang University12 enrolled1 locationNCT06999031
Recruiting
Early Phase 1
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
CD19-positive Relapsed or Refractory B-cell Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.10 enrolled1 locationNCT06092047
Recruiting
Early Phase 1
Personalized KSX01-TCRT in Patients With Advanced Solid Tumors
Refractory Solid TumorsRelapsed Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences12 enrolled1 locationNCT06150365
Recruiting
Early Phase 1
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
Relapsed/refractory LymphomaRelapsed/Refractory Leukemia
Affiliated Hospital of Nantong University9 enrolled1 locationNCT06756321